Evaluating the effectiveness of sequential therapy with Mitomycin-C and Gemcitabine for bladder cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the safety and effectiveness of sequential intravesical instillation of Mitomycin-C and Gemcitabine in patients with high-risk non-muscle invasive bladder cancer who are unresponsive to BCG treatment. It is a Phase 2, multi-institutional, open-label study that will measure the one-year recurrence-free survival rate among participants. Secondary outcomes will include progression-free survival, cystectomy-free survival, cancer-specific survival, overall survival, and safety profiles. The study will involve patients who meet specific histological criteria and have undergone recent bladder examinations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. a patient over the age of 20
2. Patients who are willing and able to complete a written test subject consent/approval for this examination.
3. Histologically confirmed high-risk NMIBC (according to AUA guidelines; High-grade T1 disease, any recurrent high-grade Ta, high-grade Ta \>3 cm, high-grade Ta that is multifocal, any carcinoma in situ, any BCG failure in high-grade patients, any variant histology, any lymphovascular invasion, and any high-grade prostatic urethral involvement) with prior BCG therapy.
4. The most recent bladder examination/TURBT must be performed within 8 weeks before the initial administration of the trial treatment. Patients with high risk NMIBC who received proper BCG treatment but did not respond to BCG
5. Patients who are not eligible for a radical bladder resection or who have refused surgery.
6. Patient who are not being pregnant or breast feeding until the study period.

Exclusion Criteria:

1. Patient diagnosed with muscle-invasive bladder cancer at TURBT
2. If upper urinary tract urothelial cancer is accompanied by imaging
3. If the imaging indicates extravesical involvement (cT3)
4. Imaging shows lymph node metastasis (short-axis 15mm or more) or distant metastasis
5. In a biopsy, non-transitional cell histology is dominant, or only non-transitional cell tissue is present (primary squamous cell carcinoma, primary adenocarcinoma, small cell carcinoma, sarcoma, carcinosarcoma, paraganglioma, melanoma, lymphoma)
6. In the case of receiving systemic cytotoxic chemotherapy for other cancers within 3 years
7. If patient have a history of pelvic radiation therapy for other cancers within 3 years
8. If patient have a history of receiving Mitomycin-c or gemcitabine in the bladder within 3 years. The exception is cases used for the purpose of injection therapy of anticancer drugs in the early bladder cancer
9. If patient has a history of allergy to mitomycin-c or gemcitabine
10. Cystoscopy shows a tumor in the prostate urethra
11. Patients who have participated in studies using clinical trial drugs and are currently receiving clinical trial drugs or who have used clinical trial drugs or clinical trial medical devices within 4 weeks prior to the date of initial treatment
12. After post-cystoscopy/TURBT, the patient received intravesical chemotherapy prior to the start of trial treatment
13. Thrombocytopenia, coagulopathy or bleeding tendency patient.
14. Pregnant or breast-feeding women
15. If patient treated yellow fever vaccine or phenytoin
16. Dysfunction of liver or kidney (GFP≤30)
17. If patient undergo severe myelosuppression
18. If patient complicated severe infection
19. If patient definitely diagnosed interstitial lung disease or lung fibrosis by chest X-ray.
20. If patient conduct chest radiotherapy.

Where it's running

• National Cancer Center
  Goyang-si, South Korea Recruiting

Study contacts

• Principal investigator: Ho Kyung Seo, MD — National Cancer Center, Korea
• Study coordinator: Ho Kyung Seo, MD
• Email: seohk@ncc.re.kr
• Phone: 82-31-920-1678

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• Urinary Cell-Free DNA Test for Urothelial Cancer Origin

  This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.

  Recruiting Ruijin Hospital · Shanghai · NCT07888374

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• Sac-TMT and pembrolizumab with chemoradiation for bladder muscle invasion

  This trial tests whether adding Sac-TMT and pembrolizumab to chemoradiation helps people with muscle-invasive bladder cancer live longer without the cancer growing or returning.

  Recruiting at 10 sites Phase 3 Merck Sharp & Dohme LLC · Kaohsiung City and 9 other locations · NCT07829783

• Personalized 3D Tumoroids from Your Tumor to Test Treatments

  Researchers are using patient tumor tissue and blood to grow personalized 3D, vascularized tumoroids with autologous immune cells to help tailor treatments for kidney, bladder, and prostate cancers.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07820566

• Irreversible Electroporation for Recurrent Pelvic Tumors

  This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT07782164

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.